"The test, called Lumipulse, measures two proteins in plasma: pTau217 and ß-Amyloid 1-42. These proteins clump together to form plaques in the brains of people with Alzheimer's. The ratio of these two proteins in blood is highly correlated with the presence or absence of amyloid plaques in the brain, an important signature of Alzheimer's. FDA approval means the test meets federal standards for safety and effectiveness, and it can now be used in certified clinical laboratories to help assess Alzheimer's disease."
"A Blood Test: Easier Than a Spinal Tap This is a big step forward because, until now, diagnosing Alzheimer's typically required more invasive and expensive tests. For a long time, Alzheimer's could only be definitively diagnosed postmortem via autopsy, when plaques could be seen directly in brain tissue. Advances in the last two decades have enabled earlier and more accurate diagnosis."
An FDA-approved blood test, Lumipulse, measures plasma pTau217 and ß-Amyloid 1-42, using their ratio to indicate presence of brain amyloid plaques. The protein ratio correlates highly with amyloid plaque status, an important signature of Alzheimer's disease. The test can be performed in certified clinical laboratories and meets federal safety and effectiveness standards. The blood test is much less invasive and less expensive than PET scans or cerebrospinal fluid testing via lumbar puncture. The test is intended for people who show cognitive symptoms and is not meant for routine early screening of healthy, asymptomatic individuals. Test usefulness depends on balancing false positives and false negatives.
Read at Psychology Today
Unable to calculate read time
Collection
[
|
...
]